28.54
+5.08%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enovis
From its filings with the US Securities and Exchange Commission
Enovis is based in Lewisville, Texas and is incorporated in Delaware. Its shares trade on NYSE under the ticker ENOV. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2025, it reported revenue of $2.25bn and a net loss of $1.18bn. At that date it held total assets of $3.83bn and shareholders' equity of $1.49bn. By region, United States accounted for 57.6%, followed by Foreign locations at 42.4%.
Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system (“EGX”), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.
During the year ended December 31, 2025, we completed four acquisitions within our Reconstructive segment and three acquisitions within our Prevention & Recovery segment. These small acquisitions added complementary prevention & recovery product offerings, expanded distribution partners for the Company’s surgical implant products in Europe, and added a complementary surgical product technology. See Note 5 “Acquisitions and Divestitures” for further information.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 May 2008
- Employees
- 7,802
- Website
- enovis.com ↗
- Head office
- 2900 LAKE VISTA DRIVE, LEWISVILLE, TX, 75067
- Incorporated in
- DE
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Sharon WienbarIndependent Chairman of the Board$331,889
- Mr. Damien McdonaldChief Executive Officer, Director, since 2025
- Mr. Phillip BerryChief Financial Officer, Senior Vice President$3.4m
- Mr. Terry RossGroup President - Prevention and Recovery
- Mr. Louie VogtGroup President - Reconstructive
- Ms. Patricia LangChief Human Resources Officer, Senior Vice President$2.3m
- Mr. Daniel PryorExecutive Vice President - Strategy and Business Development$3.5m
- Mr. Bradley TandySenior Vice President, Chief Legal Officer$2.1m
- Mr. Brady ShirleyDirector, since 2016$2.7m
- Ms. Barbara BodemIndependent Director$291,889
- Mr. Liam KellyIndependent Director$291,889
- Ms. Angela LalorIndependent Director$311,889
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 84
- Social
- 94
- Governance
- 47
- Direct emissions (scope 1)
- 2,321 t
- Energy emissions (scope 2)
- 16,625.6 t
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enovis Corp is headquartered in Wilmington, Delaware with 7,802 employees.
- The company has been publicly traded since 2008-05-08.
- Enovis operates in two business segments: Prevention & Recovery and Reconstructive.
Weaknesses
- The source description mentions 6,800 employees which conflicts with the provided 7,802 employee count.
- The source description states the company went IPO in 2008 but does not specify the exact date.
- The source description does not mention the company's website or ISIN.
Opportunities
- The company's focus on medical technology growth presents opportunities for expansion in healthcare markets.
- Developing clinically differentiated solutions could lead to new market opportunities.
- The company's product range for reconstructive surgery, rehabilitation, pain management, and physical therapy may attract growing market demand.
Threats
- The source description is untrusted and contains conflicting information about employee count.
- The company's reliance on specific medical device segments may expose it to market volatility.
- The untrusted source may lead to inaccurate financial data for investors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.